Innocan Pharma Showcases Exciting LPT-CBD Findings
Innocan Pharma Corporation, a leader in innovative pharmaceutical solutions, recently released groundbreaking results regarding its product, LPT-CBD. The company announced a significant development in the field of CBD-based therapeutics, demonstrating prolonged plasma CBD levels after a single injection in Göttingen minipigs, an established model for drug safety assessment.
Study Details and Procedure
The research involved administering ascending doses of LPT-CBD through subcutaneous injections to six animals—three Göttingen minipigs and three rabbits. Over the course of the study, the pharmacokinetics and preliminary safety parameters were closely monitored. The administration to minipigs revealed CBD concentrations retained in their plasma for an impressive duration of 28 days.
Key Findings from the Research
This examination highlighted a few pivotal observations:
- The extended duration of CBD presence in plasma confirmed the potential effectiveness of LPT-CBD.
- The metabolization of CBD in minipigs demonstrated similarities to human metabolic processes, reinforcing the model's relevance.
- Throughout the study, no adverse effects surfaced in minipigs, suggesting an excellent tolerability profile for the drug.
- Minipigs displayed minimal local reactions and only slight histopathological changes post-injection.
The Significance of Göttingen Minipigs in the Study
Göttingen minipigs are widely acknowledged in the scientific community as a critical non-rodent model for assessing drug safety. Their anatomical and physiological similarities to humans make them a crucial part of pharmacokinetics and drug evaluation. Innocan’s study reassures the scientific community regarding the effectiveness and safety profiles of CBD-based therapies.
Statements from Key Personnel
Professor Chezy Barenholz, Head of the Advisory Board at Innocan, remarked, "This study, along with several undertaken in varied animal models, confirms the sustained release of CBD following a single subcutaneous injection of LPT-CBD. The positive safety profile identified establishes promising evidence for its potential in human applications.”
Plans for Further Development
Dr. Eyal Kalo, Innocan's Vice President of Research and Development, mentioned, "We have achieved alignment with the FDA regarding our non-clinical development strategy. This study lays a solid groundwork for future explorations into LPT-CBD’s pharmacokinetics and safety, pursuing regulatory compliance."
About Innocan Pharma
Innocan Pharma is recognized as a frontrunner in the pharmaceutical industry, particularly in the enhancement of drug delivery systems. They have innovated a unique platform that utilizes CBD-loaded liposomes, promoting effective and sustained delivery of this compound for pain management therapies. Additionally, Innocan is active in the wellness sector, developing an array of skincare and self-care products aimed at a healthier lifestyle, operating through their subsidiary, BI Sky Global Ltd.
Contact Information
To connect with Innocan Pharma, you can reach out to:
Iris Bincovich, CEO
Phone: +1 5162104025
Phone: +972-54-3012842
Phone: +442037699377
Email: info@innocanpharma.com
Frequently Asked Questions
What are the main findings of Innocan's LPT-CBD study?
The study found that LPT-CBD injected into Göttingen minipigs resulted in prolonged plasma CBD levels for up to 28 days with no observed adverse effects.
Why are Göttingen minipigs used in drug safety assessments?
Göttingen minipigs possess physiological similarities to humans, making them an ideal model for studying drug metabolism and safety.
What did the study reveal about CBD metabolism?
The metabolism of CBD in minipigs closely resembled that seen in humans, indicating the potential for human therapeutic applications.
What are Innocan's future plans for LPT-CBD?
Innocan aims to continue studies under FDA compliance, setting the stage for human trials based on the promising results from their animal studies.
How does Innocan's product align with wellness trends?
Innocan is committed to promoting a healthier lifestyle through its portfolio of innovative wellness products, including self-care solutions and CBD-based therapeutics.
